- Volume 16 Issue 17
DOI QR Code
Clinical Implication of EGF A61G Polymorphism in the Risk of Non Small Cell Lung Adenocarcinoma Patients: A Case Control Study
- Masroor, Mirza ;
- Amit, Jain ;
- Javid, Jamsheed ;
- Mir, Rashid ;
- Prasant, Y ;
- Imtiyaz, A ;
- Mariyam, Z ;
- Mohan, Anant ;
- Ray, PC ;
- Saxena, Alpana
- Published : 2015.12.03
Background: The epidermal growth factor (EGF) plays important roles in non-small cell lung cancer (NSCLC) susceptibility and functional polymorphism in the EGF (+61A/G) gene has been linked to increased risk of NSCLC. This study aimed to evaluate the role of the EGF +61A/G polymorphism in risk of NSCLC adenocarcinoma (ADC) occurrence and survival in an Indian population. Materials and Methods: This casecontrol study included 100 histopathologically confirmed NSCLC (ADC) patients and 100 healthy controls. EGF (A61G) was genotyped by AS-PCR to elucidate putative associations with clinical outcomes. The association of the polymorphism with the survival of NSCLC patients was estimated by Kaplan-Meier curves. Results: It was found that EGF 61AG heterozygous and GG homozygous genotype is significantly associated with increased risk of NSCLC (ADC) occurrence compared to AA genotype, [OR 2.61 (1.31-5.18) and 3.25 (1.31-8.06), RR 1.51(1.15-2.0) and 1.72 (1.08-2.73) and RD 23.2 (6.90-39.5) and 28.53(7.0-50.1) for heterozygous AG (p=0.005) and homozygous GG (p=0.009)]. Patients homozygous for the G allele exhibited a significantly poor overall survival. The median survival time for patients with EGF 61 AA, AG, and GG genotypes was 10.5, 7.4, and 7.1 months (p=0.02), respectively. NSCLC (ADC) patients with GG + AG exhibited 7.3 months median survival compared to the AA genotype (p=0.009). Conclusions: The present study revealed that the EGF A61G genotype may be a novel independent prognostic marker to identify patients at higher risk of occurrence and an unfavourable clinical outcome.
EGF gene (+61A/G) polymorphism;AS-PCR;NSCLC (ADC) patients
- Aaronson SA (1991). Growth factors and cancer. Science 1991. 254, 1146-53. https://doi.org/10.1126/science.1659742
- Alberg AJ, Brock MV, Samet JM (2005). Epidemiology of lung cancer: Looking to the future. J Clin Oncol, 23, 3175-85. https://doi.org/10.1200/JCO.2005.10.462
- Araujo A, Ribeiro R, Azevedo I, et al (2007). Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer-a review of the literature. Oncologist, 12, 201-10. https://doi.org/10.1634/theoncologist.12-2-201
- Carpenter G, Cohen S (1990). Epidermal growth factor. J Biol Chem, 265, 7709-12.
- Ciardiello F, Tortoa G (2008). EGFR antagonist in cancer treatment. N Engl J Med, 358, 1160-74. https://doi.org/10.1056/NEJMra0707704
- Ciardiello F, Tortoa G (2001). A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res, 7, 2958-70.
- Costa BM, Ferreira P, Costa S, et al (2007). Association between functional EGF+61 polymorphism and glioma risk. Clin Cancer Res, 13, 2621-6. https://doi.org/10.1158/1078-0432.CCR-06-2606
- Gan HK, Burgess AW, Clayton AHA, et al (2012). Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res, 72, 2924-30. https://doi.org/10.1158/0008-5472.CAN-11-3898
- Goto Y, Ando T, Goto H, et al (2005). No association between EGF gene polymorphism and gastric cancer. Cancer Epidemiol Biomarkers Prev, 14, 2454-6. https://doi.org/10.1158/1055-9965.EPI-05-0401
- Goustin AS, Leof AB, Shipley GD (1986). Growth factors and cancer. Cancer Res, 46, 1015-1029.
- Harris R, Chung E, Coffey RJ, et al (2003). EGF receptor ligands. Exp Cell Res, 284, 2-13. https://doi.org/10.1016/S0014-4827(02)00105-2
- Hu-Lieskovan S, Vallbohmer D, Zhang W, et al (2011). EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clin Cancer Res, 17, 5161-9. https://doi.org/10.1158/1078-0432.CCR-10-2666
- Hynes NE, Lane HA (2005). ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer, 5, 341-54. https://doi.org/10.1038/nrc1609
- Ichiro Okamoto, Florian Roka, Julia Krogler, et al (2006). The EGF A61G polymorphism is associated with disease-free period and survival in malignant melanoma. Journal of Investigative Dermatology, 126, 2242-6. https://doi.org/10.1038/sj.jid.5700377
- Kang H, Choi JE, Lee WK, et al (2007). +61A>G polymorphism in the EGF gene does not increase the risk of lung cancer. Respirology, 12, 902-5. https://doi.org/10.1111/j.1440-1843.2007.01152.x
- Kenneth K. Tanabe, Antoinette Lemoine, et al (2008). Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis, JAMA, 299, 53-60.
- Laurence DJ, Gusterson BA (1990). The epidermal growth factor: A review of structural and functional relationships in the normal organism and in cancer cells. Tumor Biol, 11, 229-61. https://doi.org/10.1159/000217659
- Lim Y, Kim JW, Song JY, et al (2005). Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neurosci Lett, 374, 157-60. https://doi.org/10.1016/j.neulet.2004.10.055
- Li T, Ke-Wei Ren, and Peng-Fei Liu (2012). Meta-analysis of epidermal growth factor polymorphisms and cancer risk: involving 9,779 cases and 15,932 controls. DNA Cell Biol.
- Moulder SL, Yakes FM, Muthuswamy SK, et al (2001). Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/ neu (erbB2) overexpressing breast cancer cells in vitro and in vivo. Cancer Res, 61, 8887-95.
- Naruke T, Tsuchiya R, Kondo H, et al (1997). Implications of staging in lung cancer. Chest, 112, 242-8. https://doi.org/10.1378/chest.112.4_Supplement.242S
- Salomon DS, Brandt R, Ciardello F, et al (1995). Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol, 19, 183-232. https://doi.org/10.1016/1040-8428(94)00144-I
- Shahbazi M, Pravica V, Nasreen N, et al (2002). Association between functional polymorphism in EGF gene and malignant melanoma. Lancet, 359, 397-401. https://doi.org/10.1016/S0140-6736(02)07600-6
- Spira A, Ettinger DS (2004). Multidisciplinary management of lung cancer. N Engl J Med, 350, 379-92. https://doi.org/10.1056/NEJMra035536
- Tabernero J, Macarulla T, Ramos FJ, et al (2005). Novel targeted therapies in the treatment of gastric and esophageal cancer. Ann Oncol, 16, 1740-8. https://doi.org/10.1093/annonc/mdi355
- Teixeira A, et al (2008). Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients. Clin Cancer Res, 14, 3367-71. https://doi.org/10.1158/1078-0432.CCR-07-5119
- Vauleon E, Auger N, Benouaich-Amiel A, JY, Thillet J, Sanson M: The 61 A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma. Cancer Genet Cytogenet, 172, 33-37.
- Wu G, Hasenberg T, Magdeburg R, et al (2009). Association between EGF, TGF-beta1, VEGF gene polymorphism and colorectal cancer. World J Surg, 33, 124-9. https://doi.org/10.1007/s00268-008-9784-5
- Ying Piao, Liu Z, Ding Z, et al (2013). EGF +61A>G polymorphism and gastrointestinal cancer risk: a HuGE review and meta-analysis. Gene, 519, 26-33. https://doi.org/10.1016/j.gene.2013.01.057
- Zhang YM, Cao C, Liang K (2010). Genetic polymorphism of epidermal growth factor 61A>G and cancer risk: a metaanalysis. Cancer Epidemiol, 34, 150-6. https://doi.org/10.1016/j.canep.2010.02.004
- Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study vol.37, pp.8, 2016, https://doi.org/10.1007/s13277-016-4930-4
- EGF+61 A>G polymorphism is not associated with lung cancer risk in the Brazilian population pp.1573-4978, 2019, https://doi.org/10.1007/s11033-019-04702-0